A study published in the British Journal of Pharmacology on 3 March, led by University of Queensland researchers Associate Professor Trent Woodruff and Dr John Lee, has found the drug “PMX205” extends the life of mice that have a SOD1 mutation, when administered before or during very early disease onset. More studies are now underway to determine the safety of PMX205 before it can be tested in humans. 'Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis' tttp://onlinelibrary.wiley.com/doi/10.1111/bph.13730/full
Postive results for PMX205 in mice with SOD1 mutation
Latest News
Every Moment Matters - Evaluating the Impact of MND
Being diagnosed with MND brings changes, challenges and extra considerations for a person living with the condition, as well as to their carers a...
Getting Prepared for Holiday Period - Things to Think About as MND Carers
The traditional festive season is upon us…putting up Christmas trees and decorations, pondering presents to give to others, planning for celebrations,...
MND NSW Privacy Policy
We have reviewed the MND NSW Privacy Policy, in accordance with legislative responsibilities. If you would like to review our Privacy Policy you can r...
Your Opinion Matters: Ways to Shape the Future of MND
At any given time, there are a number of ways to get involved and have your say about matters that are important to you. Such as, disability supports...